The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.
SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.
Fund VI will focus on investments in industrials and healthcare businesses with proven technologies and solutions positioned to deliver high performance and value-add to their customers
Company appoints five new independent directors to reconstituted board
Investment in response to increased demand for North American-based chemistry services
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Subscribe To Our Newsletter & Stay Updated
